Physician profile
David M Ellison
NPI 1740235928
$32,638.44
in general payments reported to CMS, 2019-2025
100 companies · $5,524 in 2025
The $5,524 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,825 · 2020: $5,054 · 2021: $4,089 · 2022: $4,828 · 2023: $4,306 · 2024: $5,013 · 2025: $5,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,547.68 |
| Education | $295.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $2,882.31 | 2019-2025 | Reblozyl, Pomalyst, Abecma |
| Merck Sharp & Dohme LLC | $2,534.87 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,908.79 | 2019-2025 | |
| Pfizer INC. | $1,556.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,553.38 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Astrazeneca Pharmaceuticals LP | $1,447.31 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Genentech USA, INC. | $1,295.89 | 2019-2025 | Phesgo, Venclexta, Polivy |
| Janssen Biotech, INC. | $1,186.49 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $1,184.14 | 2019-2025 | |
| Amgen INC. | $1,156.83 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Seagen INC. | $931.28 | 2019-2025 | Tukysa, Padcev, Adcetris |
| Regeneron Healthcare Solutions, INC. | $788.29 | 2019-2025 | Libtayo |
| Lilly USA, LLC | $777.12 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $752.01 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $699.74 | 2020-2025 | Ojjaara, Zejula, Jemperli |
Show all 99 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $665.18 | 2019-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Gilead Sciences, INC. | $574.18 | 2021-2025 | Trodelvy |
| Eisai INC. | $526.06 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $493.99 | 2019-2025 | Zepzelca |
| Astellas Pharma US INC | $483.23 | 2019-2025 | Xospata, Cresemba, Vyloy |
| Mckesson Specialty Care Distribution, LLC | $465.79 | 2019-2020 | |
| Daiichi Sankyo INC. | $457.53 | 2019-2025 | Datroway, Enhertu, Injectafer |
| Abbvie INC. | $402.37 | 2020-2025 | |
| Taiho Oncology, INC. | $397.41 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $392.60 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Aveo Pharmaceuticals, INC. | $382.25 | 2022-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $367.19 | 2019-2025 | |
| Kite Pharma, INC. | $360.32 | 2021-2025 | Yescarta |
| Puma Biotechnology, INC. | $261.91 | 2019-2024 | |
| Sobi, INC | $261.58 | 2022-2025 | |
| Tersera Therapeutics LLC | $253.11 | 2019-2025 | Zoladex, Xermelo |
| Alexion Pharmaceuticals, INC. | $249.10 | 2019-2024 | Ultomiris |
| Array Biopharma INC | $232.57 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Onmark, INC. | $226.63 | 2022 | |
| Emd Serono, INC. | $184.60 | 2019-2025 | Bavencio |
| Acrotech Biopharma INC. | $178.78 | 2021-2025 | Beleodaq |
| Stemline Therapeutics INC. | $178.07 | 2023-2025 | Orserdu, Elzonris |
| Adc Therapeutics America, INC. | $177.02 | 2022-2025 | |
| Novocure INC. | $174.40 | 2019-2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Ipsen Biopharmaceuticals, INC | $171.49 | 2019-2025 | Onivyde, Somatuline Depot |
| Pharmaessentia USA Corporation | $165.21 | 2022-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $159.03 | 2022-2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.29 | 2021-2025 | |
| Beone Medicines USA, INC. | $131.89 | 2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $131.73 | 2020-2025 | Xpovio |
| Servier Pharmaceuticals LLC | $122.07 | 2022-2024 | |
| Morphosys, US INC. | $117.97 | 2021-2023 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $112.74 | 2019-2023 | Imbruvica |
| Alnylam Pharmaceuticals INC. | $109.61 | 2021-2025 | Givlaari |
| Exelixis INC. | $105.40 | 2019-2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $90.62 | 2021-2025 | Qinlock, Tgct |
| Foundation Medicine, INC. | $89.08 | 2020 | |
| Eusa Pharma (US) LLC | $84.69 | 2021-2022 | |
| Springworks Therapeutics, INC. | $83.42 | 2024-2025 | Ogsiveo, Gomekli |
| Mirati Therapeutics, INC. | $83.33 | 2023 | Krazati |
| Azurity Pharmaceuticals, INC. | $81.45 | 2025 | Danziten |
| G1 Therapeutics, INC. | $78.83 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $70.96 | 2024-2025 | Monoferric, Cosela |
| Epizyme, INC. | $70.88 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $68.06 | 2023-2024 | Orgovyx |
| Dova Pharmaceuticals | $65.58 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $64.12 | 2024 | Provenge |
| Iovance Biotherapeutics, INC. | $58.87 | 2025 | Amtagvi |
| Legend Biotech USA INC. | $58.15 | 2025 | Carvykti |
| Teva Pharmaceuticals USA, INC. | $55.76 | 2019-2020 | |
| Geron Corporation | $53.28 | 2025 | Rytelo |
| Immunocore Limited | $51.42 | 2024-2025 | Kimmtrak |
| Acceleron Pharma, INC. | $50.92 | 2021 | |
| Aurobindo Pharma USA, INC. | $48.23 | 2020 | |
| Fennec Pharmaceuticals, INC. | $46.97 | 2024 | Pedmark |
| Secura Bio, INC. | $45.74 | 2020-2021 | |
| Partner Therapeutics, INC. | $41.14 | 2019-2020 | |
| Beigene USA, INC. | $40.81 | 2023 | Brukinsa |
| Lexicon Pharmaceuticals, INC. | $38.98 | 2019 | |
| Kyowa Kirin, INC. | $37.96 | 2021-2025 | |
| Myovant Sciences INC. | $36.38 | 2021 | |
| Spectrum Pharmaceuticals INC. | $35.68 | 2024-2025 | Rolvedon |
| Sun Pharmaceutical Industries INC. | $35.51 | 2019-2021 | |
| Tempus Ai, INC | $34.77 | 2025 | Xt Cdx |
| Shield Therapeutics INC | $30.55 | 2025 | |
| Verastem, INC. | $28.88 | 2019 | |
| Cti Biopharma Corp. | $26.87 | 2022-2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $25.23 | 2020-2022 | |
| Genmab U.S., INC. | $24.05 | 2024 | Epkinly |
| Tolmar, INC. | $23.37 | 2025 | Rubraca, Eligard |
| Verity Pharmaceuticals INC. | $23.37 | 2025 | Trelstar |
| Pharmaand Gmbh | $23.37 | 2025 | Rubraca |
| Menarini Silicon Biosystems, INC. | $21.52 | 2023 | Cellsearch |
| Recordati_rare_diseases_inc. | $21.41 | 2025 | Sylvant |
| Medtronic, INC. | $20.62 | 2022 | |
| Avyxa Pharma, LLC | $20.07 | 2025 | |
| Cycle Pharmaceuticals INC | $19.63 | 2025 | Phyrago |
| Syndax Pharmaceuticals, INC. | $19.31 | 2025 | |
| Progenics Pharmaceuticals, INC. | $16.82 | 2025 | |
| Blueprint Medicines Corporation | $16.52 | 2021 | |
| Shire North American Group INC | $16.22 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.13 | 2024 | Empaveli |
| Blue Earth Diagnostics | $15.84 | 2021 | |
| Advanced Accelerator Applications | $15.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,788.28 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.